<DOC>
	<DOC>NCT01965730</DOC>
	<brief_summary>This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events</brief_summary>
	<brief_title>Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Aortic Diseases</mesh_term>
	<mesh_term>Aminocaproic Acid</mesh_term>
	<criteria>Ability to sign informed consent Elective cardiac surgery patients undergoing primary surgery involving circulatory arrest Inability to sign informed consent Baseline hypercoagulable condition as defined in medical record Coronary disease with untreated lesions or recent coronary stent placement Severe renal dysfunction (ESRD) as documented in medical record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dilated ascending aorta</keyword>
</DOC>